Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
BEIJING IMMUNOAH PHARMATECH CO., LTD. is active in the Biotechnology & Pharmaceuticals technology area with a company patent portfolio that currently shows 1 pending office action. This single action indicates a very specific point of engagement with the patent office. The presence of 1 pending office action suggests that the company's current prosecution resources are dedicated to a single matter within this complex technical field.
The organizational structure of this prosecution is highly centralized, involving 1 distinct examiner and 1 distinct art unit. This means that the pending office action is not distributed across different units or individuals, but is instead focused in one place. Such a concentrated footprint allows for a direct and consistent dialogue with the patent office, as there are no competing examiner perspectives to manage within the current portfolio.
MOSELEY II, NELSON B is identified as the busiest examiner, holding 1 busiest examiner pending action. Since the total number of pending office actions is 1, this examiner is handling the company's active prosecution. The alignment of 1 distinct examiner with 1 distinct art unit for this single action highlights a streamlined and focused approach to the company's current patent acquisitions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036144 | FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF | MOSELEY II, NELSON B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18036144 | FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF | MOSELEY II, NELSON B | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18036144 | FUSION PROTEIN TARGETING BOTH CD3 AND CD137, PREPARATION METHOD THEREFOR AND USE THEREOF | MOSELEY II, NELSON B | 1642 | §103§112 | Non-Final OA | — | Pending | May 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial